CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 102 enrolled
Drug / intervention
Olopatadine 0.6% / Azelastine 137 mcgdrug
Likely dose
Olopatadine 0.6% / Azelastine 137 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00772304
NCT00772304Phase 4Completed
CompareCT.gov

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Alcon Research·interventional·Posted Oct 15, 2008·Updated Mar 2, 2010

In Brief

A Phase 4 clinical trial evaluating Olopatadine 0.6% / Azelastine 137 mcg for Allergic Rhinitis. Completed, enrolled 102 participants across 1 site.

Detailed Summary

To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.7 years ago

Interventions

Olopatadine 0.6% / Azelastine 137 mcgdrug

single dose; 2 sprays per nostril